A Phase 1, Randomized, Open-Label, Parallel Group Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants
Latest Information Update: 03 Sep 2024
At a glance
- Drugs Bepirovirsen (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors GSK
Most Recent Events
- 30 Aug 2024 Status changed from recruiting to completed.
- 04 Apr 2024 Planned number of patients changed from 200 to 160.
- 04 Apr 2024 Planned End Date changed from 30 May 2024 to 15 May 2024.